Peer Papers
Enhanced Drug Release of PLGA Nanoparticle Modified with Polymers: Chitosan
Abstract: The biodegradable polymer poly(lactic-co-glycolic acid) (PLGA) is a biomaterial with great potential as a drug delivery carrier and a tissue engineering scaffold. Using diclofenac sodium (DS) as a drug model, PLGA/DS nanoparticles were synthesized by...
Size Optimization Bromelain Loaded Nanocarriers by Box Behnken Design
ABSTRACT Bromelain (BRN) is an extensive product of investigation, regarded as effective naturally produced anticancer agents. Heterogeneity of tumors amongst patients and within disease, generates a necessity of personalization of nanomedicine. The size of...
CENTRAL COMPOSITE FACE-CENTERED DESIGN-BASED FAVIPIRAVIR-LOADED PLGA
ABSTRACT Objective: The objective of this study is to fabricate favipiravir-loaded PLGA nanoparticulate systems that can increase the solubility along with the sustained release of favipiravir. Methods: The favipiravir-loaded Poly (D, L-lactic-co-glycolide) (PLGA)...
Inhalable dry powder containing lipid polymer hybrid nanoparticles of Nintedanib esylate: In vitro and in vivo evaluations
Abstract: The key objective of this research work was to develop and evaluate dry powder for inhalation containing lipid polymer hybrid nanoparticles (LPHNPs) loaded with Nintedanib esylate (NE) to target deep lung for the treatment of idiopathic pulmonary fibrosis...
SURFACE MODIFIED POLYMERIC NANOPARTICLES FOR ENHANCING DRUG DELIVERY OF METHOTREXATE IN THE BRAIN BY BLOCKING EFFLUX TRANSPORTERS
Abstract: The aim of the present study was to develop, optimize, and evaluate methotrexate containing poloxamer 407 coated polymeric nanoparticles to enhance the concentration of drug in the brain. In the present work methotrexate loaded nanoparticles were formulated...
Human beta defensin-2 loaded PLGA nanoparticles impregnated in collagen-chitosan composite scaffold for the management of diabetic wounds
Abstract Diabetic wound (DW) is the most devastating complication resulting in significant mortality and morbidity in diabetic patients. The standard treatment of DW care fails to address the prerequisites of treating DW owing to its multifactorial pathophysiology....
Formulation and Evaluation of Pralidoxime-PLGA Microspheres as Antidote against Organophosphorus Poisioning
Abstract Objective: The objective of the present work is to formulate and evaluate Pralidoxime chloride (PAM)-controlled release microspheres using poly (lactic-co-glycolic acid) (PLGA, 50: 50) as polymer and poly vinyl alcohol as surfactant. Materials and Methods:...
A tailored solution for localized drug delivery in liver cancer treatment
ABSTRACT Adjuvant chemotherapy is highly recommended for liver cancer to enhance survival rates due to its tendency to recur frequently. Localized drug-eluting implants have gained traction as an alternative to overcome the limitations of systemic chemotherapy. This...
**Methotrexate-loaded polymeric lipid hybrid nanoparticles (PLHNPs): a reliable drug delivery system for the treatment of glioblastoma
Polymeric lipid hybrid nanoparticles (PHLNPs) are core-shell nanoparticle structures made up of polymer cores and lipid shells that have properties similar to both polymeric nanoparticles and liposomes. Methotrexate (MTX) loaded PLHNPs containing tween 80, phosphatidylcholine, poly D, L-lactic-co-glycolic acid (PLGA) and glyceryl tripalmitate prepared using solvent injection and homogenisation method for a glioblastoma treatment option. The MTX-loaded PLHNPs optimised by Box–Behnken design to minimise particle size, higher entrapment efficacy and maximise MTX concentration in the brain at 4 h. The particle size, entrapment efficacy, concentration of drug in the brain at 4 h, zeta potential, and AUC(Brain)/AUC(Plasma) ratio were in the range of 173.51–233.37 nm, 70.56–86.34%, 6.38–12.38 μg/mL, 25.78–36.31 mV and 1.02–5.32. In-vitro drug release studies, cellular internalisation of optimised formulation against U-87 MG shows good anticancer effects.
**Statistically designed vitamin D3 Encapsulated PLGA **microspheres dispersed in thermoresponsive in-situ gel for nasal delivery
Vitamin D deficiency is a cause of concern across the world. It is a fat-soluble vitamin and exhibits two molecular forms (D2 and D3). The aim of the present study is the development and optimization of vitamin D3 loaded PLGA microspheres by using Box Behnken Design. Additionally, to enhance nasal permeation these microspheres were dispersed in the thermoreversible in-situ gel. Microspheres revealed particle size in the range of 9182 ± 1 nm with 75.5 ± 0.5%EE of vitamin D3. Polydispersity index and zeta potential of microspheres were found 0.509 and −7.56 mV, respectively confirming uniformity and colloidal stability. FTIR and DSC studies revealed no interaction between excipients and vitamin D3. Scanning electron microscopy demonstrated spherical morphology of microspheres. The thermoreversible in-situ dispersed with vitamin D3 loaded microspheres exhibit the gelation temperature between 35 °C to 37 °C. The viscosity of the gel was 35698–5032 cps. The gel strength was found 1.1 ± 0.2 mJ with hardness (27 g), adhesiveness (22 g), and stringiness (3.2 mm) measured by a texture analyzer. In vitro dissolution study revealed that microspheres showed 79% VD3 release. Whereas microspheres dispersed gel showed 69% of VD3 release up to one week as compared to an oily solution.